Pre-filled Syringes: Where Device Evidence Meets Drug Safety
I reviewed a clinical evaluation report last month where the manufacturer claimed equivalence to a predicate pre-filled syringe system. The device function was similar. The materials were comparable. The submission looked solid. Then the Notified Body asked one question:
In This Article
Pre-filled syringes sit at the boundary between pharmaceutical regulation and medical device regulation. This creates a unique challenge: you need device evidence that proves mechanical function, and you need drug-device interaction evidence that proves the medicinal product remains safe and effective when delivered through your system.
Most clinical evaluation reports treat these as separate domains. They document device safety. They reference drug approval files. But they fail to bridge the gap.
The MDR does not allow this separation.
The Regulatory Framework for Drug-Device Combinations
Article 1(8) of MDR 2017/745 defines a device incorporating a medicinal substance as an ancillary substance. The device has the principal intended action, but the substance plays a role. This classification triggers specific requirements.
MDCG 2022-5 clarifies the clinical evaluation pathway for these products. The guidance states that you must demonstrate:
- The safety and performance of the device function
- The compatibility between the device and the substance
- That the substance does not introduce unacceptable risks when delivered via the device
This is not a checklist. It is a logical chain. If any link is weak, the entire evaluation fails.
I have seen manufacturers submit equivalence claims based purely on device design. They compare needle gauge, barrel material, and plunger mechanism. They conclude equivalence. But they provide no data on how their specific configuration affects drug stability, particle formation, or protein aggregation.
The Notified Body rejects the file. Not because the device evidence is insufficient. Because the drug-device interaction evidence is absent.
Manufacturers treat drug stability as a pharmaceutical concern, not a device concern. They assume that if the drug is approved, and the device is safe, the combination is automatically acceptable. This assumption fails under MDR scrutiny. The device manufacturer must demonstrate that their specific device does not compromise drug integrity.
What Device Evidence Actually Means in This Context
Device evidence for a pre-filled syringe includes the standard elements: biocompatibility, mechanical integrity, needle sharpness, injection force, and usability. These are necessary. But they are not sufficient.
The device also delivers a medicinal substance into the body. This delivery must not:
- Degrade the active pharmaceutical ingredient
- Generate particles that trigger immune responses
- Alter the dose accuracy beyond acceptable limits
- Introduce leachables that interact with the drug
These risks are device-related. They arise from material selection, manufacturing processes, and design choices. They require device evidence, not just pharmaceutical data.
When I review equivalence strategies, I look for evidence that the predicate device and the candidate device have comparable drug-device interactions. This requires testing. It requires data on leachables and extractables. It requires stability studies that use the actual device configuration.
Manufacturers often reference the drug approval file. They state that the pharmaceutical company has validated drug stability. This is true. But the pharmaceutical company validated stability in a specific container closure system. If your device differs in materials, coatings, or contact surface area, that validation does not transfer.
The Gap Between Pharmaceutical Studies and Device Evidence
Pharmaceutical development includes extensive stability testing. The drug is exposed to various conditions: temperature, light, humidity, mechanical stress. These studies generate data on degradation pathways, shelf life, and storage requirements.
This data is critical. But it does not answer device-specific questions.
For example: Does the silicone coating on your plunger interact with the protein-based drug? Does your tungsten needle attachment process introduce metal particles into the solution? Does your sterilization cycle affect drug potency?
These are device risks. They require device evidence.
I have encountered cases where the drug manufacturer provided a stability certificate for the formulation in a glass vial. The device manufacturer used this certificate to support their pre-filled syringe. But the syringe used a different glass type, a different rubber stopper, and a different sterilization method.
The Notified Body requested compatibility testing. The manufacturer had none. The submission was delayed by months.
Drug stability data from pharmaceutical files supports your clinical evaluation only if the container closure system and processing conditions match your device. Any deviation requires specific compatibility testing and evidence that those changes do not compromise drug safety or efficacy.
What Notified Bodies Actually Look For
When a Notified Body reviews a clinical evaluation for a pre-filled syringe, they assess whether the manufacturer understands the dual nature of the product. They look for evidence that addresses both domains: device performance and drug integrity.
They ask:
- What is the intended drug or drug class?
- What are the known sensitivities of that drug to materials, pH, temperature, and mechanical stress?
- What materials are in direct contact with the drug in your device?
- What testing have you performed to demonstrate compatibility?
- What is the rationale for your shelf life and storage conditions?
If the clinical evaluation does not address these questions with data, the review stalls.
Notified Bodies are familiar with manufacturers who claim that the device is
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report). MDR Article 1, MDCG 2022-5
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
Deepen Your Knowledge
Read Complete Guide to Clinical Evaluation under EU MDR for a comprehensive overview of clinical evaluation under EU MDR 2017/745.
